BT: How does Novo Nordisk view competition in the obesity treatment space? VS: Obesity is a complex chronic disease affecting millions globally. Tackling it requires a collective effort — no ...

It has been a tough period for Novo Nordisk shareholders. In the summer of 2024 ... military attack,” he said at a press conference in Copenhagen.“There is no direct […] The EU will delay its response ...

According to White, no such arguments took place. “We never really even fought. He says we feuded. I don’t think I ever had a fight with him — except for maybe some emails,” White said ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 billion) in Brazil to increase production at its facility in Minas Gerais.

SAO PAULO (Reuters) - Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost production, it said on Monday. The ...

LONDON/COPENHAGEN (Reuters) - Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

LONDON/COPENHAGEN (Reuters) -Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment returns to a record 8 billion euros ($8.66 ...

It’s not HBO, it’s Max — but the new standalone logo for Warner Bros. Discovery‘s streamer now certainly looks like HBO’s at a glance. The Max streaming service has quietly launched a ...

Novo Nordisk has experienced a 50% drop due to potential ... I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus ... related death by 7% compared to placebo. There was no significant difference between the Rybelsus and placebo groups in outcomes ...